Phosphodiesterase type 5 inhibitor differentiation based on selectivity, pharmacokinetic, and efficacy profiles-Reference-Cited by-同舟云学术

Phosphodiesterase type 5 inhibitor differentiation based on selectivity, pharmacokinetic, and efficacy profiles

Published:2004-04 Issue:S1 Volume:27 Page:14-19
ISSN:0160-9289
Container-title:Clinical Cardiology
language:en
Short-container-title:Clin Cardiol

Author:

Seftel Allen D.

Publisher

Wiley

Subject

Cardiology and Cardiovascular Medicine,General Medicine

Reference30 articles.

1. Pharmacology of phosphodiesterase-5 inhibitors;Corbin;Int J Clin Pract,2002

2. Three-year update of sildenafil citrate (Viagra®) efficacy and safety;Sadovsky;Int J Clin Pract,2001

3. Cellular localization of phosphodiesterase type 11 (PDE 11) in human corpus cavernosum and the contribution of PDE11 inhibition on nerve-stimulated relaxation (abstr 922);Baxendale;J Urol,2001

4. Erectile dysfunction;Lue;N Engl J Med,2000

Cited by 52 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. An overview of conventional and investigational phosphodiesterase 5 inhibitors for treating erectile dysfunction and other conditions;Expert Opinion on Investigational Drugs;2024-08-11

2. Differences in ocular adverse events associated with phosphodiesterase-5 inhibitors: a real-world pharmacovigilance study;Expert Opinion on Drug Safety;2024-05-16

3. Emerging therapies for overactive bladder: preclinical, phase I and phase II studies;Expert Opinion on Investigational Drugs;2024-05-09

4. A real-world pilot study assessing treatment satisfaction with avanafil in patients with erectile dysfunction;Sexual Medicine;2024-02-01

5. Role of the hydrolytic-acidogenic phase on the removal of bisphenol A and sildenafil during anaerobic treatment;Environmental Monitoring and Assessment;2023-11-30